Avenue Therapeutics (ATXI) Competitors $0.21 -0.08 (-26.59%) As of 02:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. WINT, GRI, JAGX, SPRB, PBM, SCNI, PTN, AWH, TNFA, and GLMDShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Windtree Therapeutics (WINT), GRI Bio (GRI), Jaguar Health (JAGX), Spruce Biosciences (SPRB), Psyence Biomedical (PBM), Scinai Immunotherapeutics (SCNI), Palatin Technologies (PTN), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors Windtree Therapeutics GRI Bio Jaguar Health Spruce Biosciences Psyence Biomedical Scinai Immunotherapeutics Palatin Technologies Aspira Women's Health TNF Pharmaceuticals Galmed Pharmaceuticals Avenue Therapeutics (NASDAQ:ATXI) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation. Does the MarketBeat Community believe in ATXI or WINT? Avenue Therapeutics received 144 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 60.25% of users gave Avenue Therapeutics an outperform vote while only 37.50% of users gave Windtree Therapeutics an outperform vote. CompanyUnderperformOutperformAvenue TherapeuticsOutperform Votes14760.25% Underperform Votes9739.75% Windtree TherapeuticsOutperform Votes337.50% Underperform Votes562.50% Do insiders and institutionals hold more shares of ATXI or WINT? 17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by insiders. Comparatively, 0.3% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ATXI or WINT more profitable? Windtree Therapeutics' return on equity of -362.76% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avenue TherapeuticsN/A -471.57% -296.50% Windtree Therapeutics N/A -362.76%-79.65% Which has stronger earnings & valuation, ATXI or WINT? Windtree Therapeutics is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvenue TherapeuticsN/AN/A-$10.38M$18.350.01Windtree TherapeuticsN/AN/A-$20.29M-$823.470.00 Do analysts recommend ATXI or WINT? Windtree Therapeutics has a consensus price target of $350.00, indicating a potential upside of 59,021.62%. Given Windtree Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Windtree Therapeutics is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, ATXI or WINT? Avenue Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Does the media refer more to ATXI or WINT? In the previous week, Avenue Therapeutics had 4 more articles in the media than Windtree Therapeutics. MarketBeat recorded 11 mentions for Avenue Therapeutics and 7 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.66 beat Avenue Therapeutics' score of -0.37 indicating that Windtree Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avenue Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral Windtree Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAvenue Therapeutics and Windtree Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$663K$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E Ratio0.018.4326.6419.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book0.116.536.974.60Net Income-$10.38M$143.25M$3.23B$248.06M7 Day Performance-19.92%0.21%-0.98%-1.03%1 Month Performance18.84%10.92%7.70%3.50%1 Year Performance-93.88%2.44%31.32%12.68% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics1.8156 of 5 stars$0.21-26.6%N/A-91.9%$663KN/A0.014Gap DownWINTWindtree Therapeutics1.6849 of 5 stars$0.75-1.5%$350.00+46,579.1%-99.6%$2.75MN/A-0.0530Short Interest ↑Gap DownGRIGRI Bio2.0219 of 5 stars$1.28-5.2%$22.00+1,618.8%-97.5%$2.74MN/A-0.111News CoverageAnalyst ForecastShort Interest ↑Analyst RevisionGap DownJAGXJaguar Health2.545 of 5 stars$4.06-7.7%$60.00+1,377.8%-95.8%$2.74M$11.55M0.0050Positive NewsSPRBSpruce Biosciences2.3852 of 5 stars$0.06-2.4%$2.17+3,296.0%-88.3%$2.69M$4.91M-0.0720News CoverageShort Interest ↑PBMPsyence BiomedicalN/A$4.64-5.5%N/A-98.8%$2.65MN/A0.00N/AGap DownSCNIScinai Immunotherapeutics0.6511 of 5 stars$2.50-8.1%N/A-13.4%$2.50M$658K-0.0120News CoverageShort Interest ↑PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health0.9572 of 5 stars$0.08-12.5%$5.50+6,607.3%-95.6%$2.44M$9.18M-0.07110High Trading VolumeTNFATNF PharmaceuticalsN/A$0.17+6.6%N/AN/A$2.43MN/A-0.036Gap DownHigh Trading VolumeGLMDGalmed Pharmaceuticals1.0859 of 5 stars$1.45+1.4%N/A-62.7%$2.40MN/A-0.0920Gap Up Related Companies and Tools Related Companies Windtree Therapeutics Alternatives GRI Bio Alternatives Jaguar Health Alternatives Spruce Biosciences Alternatives Psyence Biomedical Alternatives Scinai Immunotherapeutics Alternatives Palatin Technologies Alternatives Aspira Women's Health Alternatives TNF Pharmaceuticals Alternatives Galmed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATXI Stock Free ATXI Stock Alerts